EXPERIENCE OF HORMONE DEPENDENT PROSTATE CANCER TREATMENT BY LUTEINISING HORMONE-RELEASING HORMONE ANTAGONIST DEGARELIX

Moscow developmental program results on assessment of luteinizing hormone-releasing hormone (gonadotrophinreleasing hormone) antagonist degarelix efficacy and tolerance in patients with prostate cancer received drug treatment in specialized outpatient polyclinic institutions of Moscow are provided in the original publication. In total 307 patients were included in the study and assigned in 3 groups: 1st (n=174) – patients with progressing prostate cancer after radical treatment (prostatectomy, radiation therapy); 2d (n=92) – patients with prostate cancer had cardiovascular diseases in history; 3d (n=41) – patients with prostate cancer with early castration refractivity occurred on the background of continuous hormone therapy by luteinizing hormone-releasing hormone antagonists. In all groups degarelix was prescribed in standard therapeutic regimen (240 mg/80 mg). Degarelix was effective in all test groups that was manifested by PSA level decrease on the background of one-year drug treatment, high control of testosterone castration level. Treatment by degarelix allowed increasing time before chemotherapy prescription (up to 12 months) in certain group of patients with biochemical progression on the background of luteinizing hormone-releasing hormone analogues administration. Degarelix tolerance was good even in patients with clinically significant cardiovascular pathology in history. In 4% of cases significant reactions were observed in the injection site after start dose administration.

prostate cancer, degrelix, cardiovascular pathology

1. Albertsen P.C., Klotz L., Tombal B. et al. Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist. Eur Urol 2014;65:565–73.

2. Anderson J., Abrahamsson P.A., Crawford D., et al. Management of advanced prostate cancer: can we improve on androgen deprivation therapy. BJU Int 2008;101:1497–1501.

3. Bosco C, et al. Eur Urol 2014, in press materials.

4. Gandaglia G, et al. Clin Genitourin Cancer. 2015;13(3): 123–30.

5. Keating, et al. J Natl Can Inst 2010;102:39–46.

6. Kurt Miller Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27). Ther Adv Urol 2015, Vol. 7(3) 105–115.

7. Nanda A, et al. JAMA 2009;302:866–73; 4.

8. Mottet N, et al. 2014 EAU Guidelines on prostate cancer.

9. Мишугин С.В., Колесников Г.П., Широкорад В.И. Результаты Российского проспективного исследования по оценке эффективности и переносимости дегареликса у больных раком предстательной железы. Онкология. Журнал им. П.А. Герцена, 1, 2015, 45–49. S.V. Mishugin, G.P. Kolesnikov, V. I. Shirokorad Results of Russian Prospective Study for Assessment of Degarelix Efficacy and Tolerance in Patients with Prostate Cancer. P.A. Hertzen Oncology. Journal, 1, 2015, 45–49.